source
- Mineralys Therapeutics raises funds ahead of pending lorundrostat hypertension approvalMineralys Therapeutics first came to market attention in 2021 when it licensed a novel hypertension candidate, lorundrostat, from Japan’s Tanabe Pharma, agreeing to a modest $1 million upfront paym…
- FDA issues new guidance for pharma on discussing unapproved drugs with payorsThe FDA has released guidance aimed at biopharma companies that are preparing to launch new therapies before they receive formal approval. The advice focuses on how companies can inform health-pla…